Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A population-based study.
Renata AbrahaoRaul C RibeiroDaphne Y LichtensztajnAaron S RosenbergTheresa H M KeeganPublished in: Pediatric blood & cancer (2018)
Our study suggests a benefit of rituximab on the treatment of AYAs and HIV patients with DLBCL. The worse survival observed among HIV-positive and uninsured patients is of concern and calls for further investigation. Careful consideration should be given on whether to recommend rituximab more often on the front-line treatment of children and HIV-positive patients with DLBCL.
Keyphrases
- hiv positive
- diffuse large b cell lymphoma
- men who have sex with men
- antiretroviral therapy
- south africa
- epstein barr virus
- hiv testing
- hiv infected
- human immunodeficiency virus
- young adults
- end stage renal disease
- ejection fraction
- chronic kidney disease
- healthcare
- health insurance
- peritoneal dialysis
- chronic lymphocytic leukemia
- patient reported outcomes
- replacement therapy
- hodgkin lymphoma